{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:06:14Z","timestamp":1787630774664,"version":"build-2736575974"},"reference-count":30,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GR 1852\/6-1 to O.G."],"award-info":[{"award-number":["GR 1852\/6-1 to O.G."]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012692","name":"K. C. Wong Education Foundation","doi-asserted-by":"publisher","award":["to Y. Zhang"],"award-info":[{"award-number":["to Y. Zhang"]}],"id":[{"id":"10.13039\/501100012692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001655","name":"Deutscher Akademischer Austauschdienst","doi-asserted-by":"publisher","award":["to Y. Zhang"],"award-info":[{"award-number":["to Y. Zhang"]}],"id":[{"id":"10.13039\/501100001655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Angiotensin-converting enzyme inhibitors (ACEi) delay progression of the inherited renal disease Alport syndrome. However, the effect of ACEis weakens gradually due to an \u201caldosterone escape\u201d. Here, we investigate if an aldosterone antagonist can counteract loss of ACEi-efficacy. COL4A3-\/- mice were treated with ramipril (ACEi), starting at 4.5 weeks of age, and spironolactone was added at 7 weeks of age. Lifespan until renal failure, as well as kidney function parameters, were investigated. Dual therapy decreased proteinuria levels compared to ACEi monotherapy. Matrix accumulation, as well as tubulointerstitial and glomerular scar-tissue formation, were significantly reduced compared to untreated mice and ACEi-monotherapy at 75 and 100 days. Lifespan in dual treated mice was extended compared to untreated mice. However, lifespan was not superior to ACEi monotherapy\u2013despite improved urea-nitrogen levels in the dual therapy group. In conclusion, adding the aldosterone-antagonist spironolactone to ACEi therapy further improved kidney function and reduced proteinuria and fibrosis. However, survival was not improved further, possibly due to premature death from side effects of dual therapy such as hyperkalemia. Thus, dual therapy could offer an effective therapy option for Alport syndrome patients with progressive proteinuria. However, the risks of adverse events require close monitoring.<\/jats:p>","DOI":"10.3390\/jcm10132958","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T02:44:39Z","timestamp":1625107479000},"page":"2958","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Organoprotective Effects of Spironolactone on Top of Ramipril Therapy in a Mouse Model for Alport Syndrome"],"prefix":"10.3390","volume":"10","author":[{"given":"Diana","family":"Rubel","sequence":"first","affiliation":[{"name":"Clinic of Nephrology and Rheumatology, University Medical Center Goettingen, 37075 Goettingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology and Rheumatology, University Medical Center Goettingen, 37075 Goettingen, Germany"},{"name":"Department of Pediatrics, Peking University First Hospital, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nenja","family":"Sowa","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology and Rheumatology, University Medical Center Goettingen, 37075 Goettingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Girgert","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology and Rheumatology, University Medical Center Goettingen, 37075 Goettingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8390-8852","authenticated-orcid":false,"given":"Oliver","family":"Gross","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology and Rheumatology, University Medical Center Goettingen, 37075 Goettingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.1016\/S0021-9258(17)37416-1","article-title":"Structure of the human type IV collagen COL4A5 gene","volume":"269","author":"Zhou","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1093\/hmg\/3.8.1269","article-title":"Mutations in the type IV collagen alpha 3 (COL4A3) gene in autosomal recessive Alport syndrome","volume":"3","author":"Lemmink","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1086\/302106","article-title":"Determination of the genomic structure of the COL4A4 gene and of novel mutations causing autosomal recessive Alport syndrome","volume":"63","author":"Boye","year":"1998","journal-title":"Am. J. Hum. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/jmg.34.4.326","article-title":"Alport\u2019s syndrome","volume":"34","author":"Flinter","year":"1997","journal-title":"J. Med. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1681\/ASN.V114649","article-title":"X-linked Alport syndrome: Natural history in 195 families and genotype-phenotype correlations in males","volume":"11","author":"Jais","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1681\/ASN.2009070784","article-title":"Genotype-phenotype correlation in X-linked Alport syndrome","volume":"21","author":"Bekheirnia","year":"2010","journal-title":"J. Am. Soc. Nephrol"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00467-013-2643-0","article-title":"Clinical and genetic features in autosomal recessive and X-linked Alport syndrome","volume":"29","author":"Wang","year":"2014","journal-title":"Pediatr. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lee, J.M., Nozu, K., Choi, D.E., Kang, H.G., Ha, I.S., and Cheong, H.I. (2019). Features of Autosomal Recessive Alport Syndrome: A Systematic Review. J. Clin. Med., 8.","DOI":"10.3390\/jcm8020178"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Zhang, Y., B\u00f6ckhaus, J., Wang, F., Wang, S., Rubel, D., Gross, O., and Ding, J. (2021). Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome. Pediatr. Nephrol., online ahead of print.","DOI":"10.1007\/s00467-021-05040-9"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1523-1755.2003.00779.x","article-title":"Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome","volume":"63","author":"Gross","year":"2003","journal-title":"Kidney Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1093\/ndt\/gfh219","article-title":"Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis","volume":"19","author":"Gross","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/ki.2011.407","article-title":"Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy","volume":"81","author":"Gross","year":"2012","journal-title":"Kidney Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1093\/ndt\/gfq797","article-title":"Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial","volume":"26","author":"Webb","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00467-015-3184-5","article-title":"Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome","volume":"31","author":"Zhang","year":"2016","journal-title":"Pediatr. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"ESCAPE Trial Group, W\u00fchl, E., Trivelli, A., Picca, S., Litwin, M., Peco-Antic, A., Zurowska, A., Testa, S., Jankauskiene, A., and Emre, S. (2009). Strict blood-pressure control and progression of renal failure in children. N. Engl. J. Med., 361, 1639\u20131650.","DOI":"10.1056\/NEJMoa0902066"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/j.ajkd.2005.03.007","article-title":"Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study","volume":"46","author":"Bianchi","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Yang, C.T., Kor, C.T., and Hsieh, Y.P. (2018). Long-term effects of spironolactone on kidney function and hyperkalemia-associated hospitalization in patients with chronic kidney disease. J. Clin. Med., 7.","DOI":"10.3390\/jcm7110459"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1159\/000368470","article-title":"Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria","volume":"39","author":"Kim","year":"2014","journal-title":"Kidney Blood Press. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/jdi.12029","article-title":"Comparison of spironolactone and trichlormethiazide as add-on therapy to renin-angiotensin blockade for reduction of albuminuria in diabetic patients","volume":"4","author":"Hase","year":"2013","journal-title":"J. Diabetes Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e12148","DOI":"10.5812\/numonthly.12148","article-title":"Effect of spironolactone on diabetic nephropathy compared to the combination of spironolactone and losartan","volume":"6","author":"Makhlough","year":"2014","journal-title":"Nephrourol. Mon."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e005288","DOI":"10.1161\/CIRCHEARTFAILURE.118.005288","article-title":"Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction","volume":"11","author":"Selvaraj","year":"2018","journal-title":"Circ. Heart Fail."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000454933","article-title":"Spironolactone treatment and effect on survival in chronic heart failure patients with reduced renal function: A propensity-matched study","volume":"7","author":"Stubnova","year":"2017","journal-title":"Cardiorenal Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00467-006-0270-8","article-title":"The effect of aldosterone blockade in patients with Alport syndrome","volume":"21","author":"Kaito","year":"2006","journal-title":"Pediatr. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ki.2013.278","article-title":"The renin-aldosterone axis in kidney transplant recipients and its association with allograft function and structure","volume":"85","author":"Issa","year":"2014","journal-title":"Kidney Int."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Gant, C.M., Laverman, G.D., Vogt, L., Slagman, M.C., Heerspink, H.J., Waanders, F., Hemmelder, M.H., and Navis, G. (2017). Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels. BMC Nephrol., 18.","DOI":"10.1186\/s12882-017-0789-x"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Wang, C.-C., Lee, A.-S., Liu, S.-H., Chang, K.-C., Shen, M.-Y., and Chang, C.-T. (2019). Spironolactone ameliorates endothelial dysfunction through inhibition of the AGE\/RAGE axis in a chronic renal failure rat model. BMC Nephrol., 20.","DOI":"10.1186\/s12882-019-1534-4"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12079-018-0466-2","article-title":"Spironolactone rescues renal dysfunction in obstructive jaundice rats by upregulating ACE2 expression","volume":"13","author":"Kong","year":"2019","journal-title":"J. Cell Commun. Signal."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/ndt\/gfz131","article-title":"New therapeutic options for Alport syndrome","volume":"34","author":"Torra","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.kint.2020.06.038","article-title":"Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome","volume":"98","author":"Yamamura","year":"2020","journal-title":"Kidney Int."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/13\/2958\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:24:19Z","timestamp":1760163859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/13\/2958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":30,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["jcm10132958"],"URL":"https:\/\/doi.org\/10.3390\/jcm10132958","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]}}}